A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: The DOLATAV study

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)477-479
Number of pages3
JournalDrug Design, Development and Therapy
Volume13
DOIs
Publication statusPublished - Jan 1 2019

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this